mPharma key facts
as of Oct 2026- Developer of a pharmaceutical data analytics platform designed to make prescription drugs accessible and affordable in emerging markets.
- mPharma is valued at approximately $113.5M as of Oct 2026 (last reported valuation).
- It has raised $89.4M; the latest was Later Stage VC in Nov 2025.
- Notable investors include Microsoft for Startups, Lux Capital, Western Technology Investment, Alchemist Accelerator, Breyer Capital — 35 tracked in total.
- Status: Privately Held (backing).
mPharma's last reported valuation, Apr 2020. Nothing priced has surfaced since.
- ·The complete investor list: 35 names
- ·Watch mPharma: the Monday email on marks, rounds and moves
mPharma funding rounds
No funding rounds for mPharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs mPharma
35+mPharma valuation
mPharma's last reported valuation was $114 million in Apr 2020. No priced round, secondary trade or fund mark has surfaced since.
mPharma investors
35 investors are on record for mPharma, including Microsoft for Startups, Lux Capital, Western Technology Investment and Alchemist Accelerator. By type, the record holds 9 venture capital firms and 1 family office.
About mPharma
Developer of a pharmaceutical data analytics platform designed to make prescription drugs accessible and affordable in emerging markets. The company's platform manages prescription drug inventory for pharmacies and their suppliers and helps them to prescribe and locate the medicines they need and report adverse drug reactions, enabling pharmacies to guarantee the medicines that are needed are always available and affordable.
- Sector
- Healthcare
- HQ
- Accra, Ghana
- Founded
- 2013
- Employees
- 425
- Website
- mpharma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.